We have released our fifth annual comprehensive investment guide and market analysis of the global neurological disease and psychiatric illness markets. The 480-page report enables investors, companies and governments to identify opportunities, calculate risks and understand the dynamics of this continually changing market.

Specific findings from The Neurotechnology Industry 2009 Report show that in 2008:

- 2 billion individuals worldwide suffered from a brain-related illness
- Over 550 public and private companies participated in neurotech worldwide
- Venture capital investment in neurotechnology fell 22% to $1.44 billion
- More than 250 venture investors were involved in neurotech financings
- Global neurotech industry revenues rose 9.0% to $144.5 billion
- Neuropharmaceuticals recorded revenues of $121.6 billion and 9.3% annual growth
- Neurodevices recorded revenues of $6.1 billion and 18.6% annual growth
- Neurodiagnostics recorded revenues of $16.8 billion and 3.7% annual growth
- The annual economic burden of brain-related illnesses is over $2 trillion

The Neurotechnology Industry 2009 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System comprehensively tracks pipelines and products in development globally to help guide strategic business development and investment decisions in neurotech.

The 2009 report provides an in-depth look at more than 16 brain and nervous system disorders and treatments in development at over 550 public and private companies, including: Alzheimer's disease, addiction, ADHD, anxiety, depression, epilepsy, migraine, mild cognitive impairment, multiple sclerosis, obesity, pain, Parkinson's disease, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, stroke and traumatic brain injury. Corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry are fully assessed with detailed insights.